Madrigal's $4.4B Bet on Gene Silencing to Conquer the MASH Market

CONSHOHOCKEN, PA – February 11, 2026 – Madrigal Pharmaceuticals, the company that broke a years-long drought in liver disease treatment, is making an aggressive move to secure its future, announcing a multi-billion dollar licensing deal to develop genetically targeted therapies for metabolic dysfunction-associated steatohepatitis (MASH).

The company has entered into an exclusive global agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA (siRNA) programs. The deal includes a $60 million upfront payment and could reach a staggering $4.4 billion if development and commercial milestones are met, plus royalties. This strategic pivot dramatically expands Madrigal's pipeline and signals a bold new chapter for a company that, just over a year ago, was celebrated for its single blockbuster drug.

A New Frontier in Precision Liver Treatment

MASH, formerly known as NASH, is a silent and progressive disease affecting over 250 million people globally, driven by rising rates of obesity and diabetes. It can lead to liver scarring (fibrosis), cirrhosis, cancer, and the need for transplantation. For years, the field was considered a “graveyard for innovators” due to repeated clinical trial failures. Madrigal changed that with Rezdiffra (resmetirom), the first and only approved therapy for MASH with moderate to advanced fibrosis.

Now, the company is looking beyond its initial success toward the next frontier: precision genetics. The newly licensed siRNA technology represents a highly targeted approach to treating MASH. These molecules are designed to act like a “dimmer switch” for specific genes inside liver cells that drive the disease. By linking the siRNA to a special ligand called GalNAc, the drug is delivered directly to hepatocytes, where it breaks down the messenger RNA (mRNA) of a target gene, reducing the production of a harmful protein.

This move aligns with a growing consensus among experts that the complexity of MASH requires a multi-pronged attack. The strategy is to combine the broad metabolic benefits of Rezdiffra with the precise, gene-silencing power of siRNA.

“siRNAs are highly liver targeted, and there are several genes implicated in MASH that could be addressed with an mRNA-knockdown approach,” said David Soergel, M.D., Chief Medical Officer of Madrigal, in a statement. “The precision of siRNA gene silencing, combined with Rezdiffra, has the potential to create the next generation of MASH treatment: genetically targeted therapies for patients with unmet needs.”

From Single-Drug Star to Pipeline Powerhouse

The deal marks a stunningly rapid transformation for Madrigal. The company has leveraged the success of Rezdiffra, which is on track to generate nearly $1 billion in sales in 2025, to aggressively build a comprehensive MASH franchise.

“At the start of 2025, Madrigal was a single-product company launching the first medication for MASH,” said CEO Bill Sibold. “Today, we have the foundational therapy in Rezdiffra, a fully enrolled F4c outcomes study, and an industry-leading MASH pipeline with more than 10 programs targeting different drivers of the disease.”

This expanded pipeline is designed to attack MASH from multiple angles. It includes:
* Rezdiffra: The foundational THR-β agonist, now being studied in patients with more advanced cirrhosis (F4c).
* MGL-2086: An oral GLP-1 receptor agonist, a class of drugs that has transformed diabetes and obesity treatment, which is entering first-in-human studies.
* Ervogastat: A Phase 2 oral DGAT-2 inhibitor, licensed from Pfizer, which is being evaluated for combination trials with Rezdiffra.
* Six siRNA Programs: The newly acquired assets for genetically targeted therapy.

This diversification strategy not only aims to address different patient segments and disease drivers but also positions Madrigal to develop its own in-house combination therapies, a key advantage in a market shifting away from monotherapy.

Navigating a Crowded and High-Stakes Market

While Madrigal holds a first-mover advantage with Rezdiffra, the MASH market—projected to exceed $30 billion by the early 2030s—is attracting fierce competition. Pharmaceutical giants like Eli Lilly and Novo Nordisk are demonstrating that their powerful GLP-1 drugs, such as tirzepatide and semaglutide, can also resolve MASH, creating a significant competitive threat. Other companies are advancing promising candidates like FGF21 analogs, which have also shown strong results in reducing liver fat and fibrosis.

In this high-stakes environment, the prevailing view is that no single drug will be a silver bullet for all patients. The future of MASH treatment lies in combination therapies that target the disease's multiple underlying biological pathways—metabolism, inflammation, and fibrosis.

Madrigal’s strategy appears to be a direct response to this reality. By building a diverse pipeline, the company is not just defending its leadership but actively working to define the next standard of care. This allows it to explore novel combinations of its own assets, potentially creating more effective treatments and building a formidable intellectual property moat around its franchise.

The High Price of Innovation

The potential $4.4 billion price tag for six preclinical programs underscores both the immense promise of siRNA technology and the high financial stakes of pharmaceutical innovation. While the upfront payment is a relatively modest $60 million, the total biobucks value places the deal among the largest licensing agreements in the biotech sector recently. It reflects a high degree of confidence in the scientific platform of its partners, Ribo and Ribocure, who are considered pioneers in RNAi technology with proprietary delivery and stabilization platforms that enhance drug efficacy and safety.

Funding this ambitious expansion is made possible by Rezdiffra's robust commercial performance. The drug's strong revenue stream provides Madrigal with the financial firepower to make bold, strategic bets that smaller companies cannot afford. By reinvesting its profits into next-generation R&D, Madrigal is signaling its long-term commitment to leading the MASH field, betting that a multi-modality approach is the ultimate key to conquering this complex and widespread disease.